The incidence of anal squamous cell carcinoma (SCCA) has been rapidly increasing in recent years. The burden of the disease is expected to increase in the forthcoming years. Men who have sex with men living with HIV (MSMLWH) have a higher incidence of SCCA than the general population. The progression of SCCA usually develops from high risk human papillomavirus (HR-HPV) infection to high grade squamous intra-epithelial lesions (HSIL). HPV infection is highly prevalent in MSMLWH and is considered the most important risk factor for SCCA in MSMLWH. Although the prevalence worldwide is largely similar, the distribution of high-risk HPV genotypes varies. Education on sexuality and lifestyle, use of condoms, fixed sexual partner, effective antiretroviral therapy (ART), smoking cessation, and preventive male circumcision could reduce HPV infection in MSMLWH. Screening and treatment of HSIL have been widely applied to prevent SCCA, but divergence still exists in many studies. When treating HSIL, patients of different ages and risk factors need more consideration to develop standardized management strategies, especially for MSMLWH. Very few studies have examined the treatment of SCCA with MSMLWH. ART has dramatically changed the treatment of SCCA in MSMLWH. The safety and outcome of treatment are still primary concerns for MSMLWH. More studies in this field are necessary to develop treatment strategies for MSMLWH.
SungHFerlayJSiegelRL, et al.Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin2021; 71(3): 209–249.
2.
de MartelCGeorgesDBrayF, et al.Global burden of cancer attributable to infections in 2018: a worldwide incidence analysis. Lancet Global Health2020; 8(2): e180–e190.
3.
SiwakESuchaczMMCielniakI, et al.Inflammatory bowel disease in adult HIV-infected patients-is sexually transmitted infections misdiagnosis possible?J Clin Med2022; 11(18): 5324.
4.
AjaniJAWinterKAGundersonLL, et al.Prognostic factors derived from a prospective database dictate clinical biology of anal cancer: the intergroup trial (RTOG 98-11). Cancer2010; 116(17): 4007–4013.
5.
Perez-GonzalezACachayEOcampoA, et al.Update on the epidemiological features and clinical implications of Human Papillomavirus Infection (HPV) and Human Immunodeficiency Virus (HIV) coinfection. Microorganisms. 2022; 10(5): 1047.
6.
SchiffmanMWentzensenN. Human papillomavirus infection and the multistage carcinogenesis of cervical cancer. Cancer Epidemiol Biomarkers Prev2013; 22(4): 553–560.
7.
WeiFGoodmanMTXiaN, et al.Incidence and clearance of anal human papillomavirus infection in 16 164 individuals, according to human immunodeficiency virus status, sex, and male sexuality: an international pooled analysis of 34 longitudinal studies. Clin Infect Dis2023; 76(3): e692–e701.
8.
DeshmukhAADamgaciogluHGeorgesD, et al.Global burden of HPV-attributable squamous cell carcinoma of the anus in 2020, according to sex and HIV status: a worldwide analysis. Int J Cancer2022; 152: 417.
9.
PoyntenIMTabriziSNJinF, et al.Vaccine-preventable anal human papillomavirus in Australian gay and bisexual men. Papillomavirus Res2017; 3: 80–84.
10.
StanleyMAWinderDMSterlingJC, et al.HPV infection, Anal Intra-epithelial Neoplasia (AIN) and anal cancer: current issues. BMC Cancer2012; 12: 398.
11.
WeiFGaisaMMD’SouzaG, et al.Epidemiology of anal human papillomavirus infection and high-grade squamous intraepithelial lesions in 29 900 men according to HIV status, sexuality, and age: a collaborative pooled analysis of 64 studies. Lancet HIV2021; 8(9): e531–e543.
12.
ClarkeMADeshmukhAASukR, et al.A systematic review and meta-analysis of cytology and HPV-related biomarkers for anal cancer screening among different risk groups. Int J Cancer2022; 151(11): 1889–1901.
13.
StierEAClarkeMADeshmukhAA, et al.International Anal Neoplasia Society's consensus guidelines for anal cancer screening. Int J Cancer2024; 154(10): 1694–1702.
14.
MoYMaJZhangH, et al.Prophylactic and therapeutic HPV vaccines: current scenario and perspectives. Front Cell Infect Microbiol2022; 12: 909223.
15.
BrothertonJMLGiulianoARMarkowitzLE, et al.Monitoring the impact of HPV vaccine in males-Considerations and challenges. Papillomavirus Res2016; 2: 106–111.
16.
LuYWangXLiP, et al.Clinical characteristics and prognosis of anal squamous cell carcinoma: a retrospective audit of 144 patients from 11 cancer hospitals in southern China. BMC Cancer2020; 20(1): 679.
17.
SilverbergMJLauBJusticeAC, et al.Risk of anal cancer in HIV-infected and HIV-uninfected individuals in North America. Clin Infect Dis2012; 54(7): 1026–1134.
18.
GravittPEWinerRL. Natural history of HPV infection across the lifespan: role of viral latency. Viruses2017; 9(10): 267.
19.
CliffordGMGeorgesDShielsMS, et al.A meta-analysis of anal cancer incidence by risk group: toward a unified anal cancer risk scale. Int J Cancer2021; 148(1): 38–47.
20.
KimJHSaraniBOrkinBA, et al.HIV-positive patients with anal carcinoma have poorer treatment tolerance and outcome than HIV-negative patients. Dis Colon Rectum2001; 44(10): 1496–1502.
21.
Alfa-WaliMAllen-MershTAntoniouA, et al.Chemoradiotherapy for anal cancer in HIV patients causes prolonged CD4 cell count suppression. Ann Oncol2012; 23(1): 141–147.
22.
ShielsMSIslamJYRosenbergPS, et al.Projected cancer incidence rates and burden of incident cancer cases in HIV-infected adults in the United States through 2030. Ann Intern Med2018; 168(12): 866–873.
23.
DuanRXuKHuangL, et al.Temporal trends and projection of cancer attributable to human papillomavirus infection in China, 2007-2030. Cancer Epidemiol Biomarkers Prev2022; 31(5): 1130–1136.
24.
LiXLiMYangY, et al.Anal HPV/HIV co-infection among Men Who Have Sex with Men: a cross-sectional survey from three cities in China. Sci Rep2016; 6: 21368.
25.
ShiojiriDMizushimaDTakanoM, et al.Anal human papillomavirus infection and its relationship with abnormal anal cytology among MSM with or without HIV infection in Japan. Sci Rep2021; 11(1): 19257.
26.
PhanuphakNTeeratakulpisarnNPankamT, et al.Anal human papillomavirus infection among Thai men who have sex with men with and without HIV infection: prevalence, incidence, and persistence. J Acquir Immune Defic Syndr2013; 63(4): 472–479.
27.
RolloFLatiniAGiulianiM, et al.Evaluation of HPV-related biomarkers in anal cytological samples from HIV-uninfected and HIV-infected MSM. Pathogens2021; 10(7): 888.
28.
NyitrayAGMasunagaKIANyoniJ, et al.Prevalence of and factors associated with anal high-risk human papillomavirus in urban Tanzanian men who have sex with men, 2011-2012. Int J STD AIDS2022; 33(7): 672–679.
29.
KahnJABelzerMChiX, et al.Pre-vaccination prevalence of anogenital and oral human papillomavirus in young HIV-infected men who have sex with men. Papillomavirus Res2019; 7: 52–61.
30.
YunihastutiETeeratakulpisarnNJeoWS, et al.Incidence, clearance, persistence and factors related with high-risk anal HPV persistence in South-East Asian MSM and transgender women. AIDS2020; 34(13): 1933–1941.
31.
GiulianoARTortolero-LunaGFerrerE, et al.Epidemiology of human papillomavirus infection in men, cancers other than cervical and benign conditions. Vaccine2008; 26(Suppl 10): K17–28.
32.
ChoiYLoutfyMRemisRS, et al.HPV genotyping and risk factors for anal high-risk HPV infection in men who have sex with men from Toronto, Canada. Sci Rep2021; 11(1): 4779.
33.
YeZHChenSLiuF, et al.Patterns of sexually transmitted Co-infections and associated factors among men who have sex with men: a cross-sectional study in Shenyang, China. Front Public Health2022; 10: 842644.
34.
WuPFHangJFStrongC, et al.Anal human papillomavirus and its associations with abnormal anal cytology among men who have sex with men. Sci Rep2020; 10(1): 3165.
35.
PoonMKLWongJPHLiATW, et al.HIV-positive MSM’s knowledge of HPV and anal cancer self-sampling: a scoping review. Curr Oncol2018; 25(1): e83–e89.
36.
ZhangZLingXLiuL, et al.Natural history of anal papillomavirus infection in HIV-negative men who have sex with men based on a Markov model: a 5-year prospective cohort study. Front Public Health2022; 10: 891991.
37.
CranstonRDCarballo-DiéguezAGundackerH, et al.Prevalence and determinants of anal human papillomavirus infection in men who have sex with men and transgender women. Int J STD AIDS2019; 30(2): 154–162.
38.
MatogaMHosseinipourMCJewettS, et al.Effects of HIV voluntary medical male circumcision programs on sexually transmitted infections. Curr Opin Infect Dis2021; 34(1): 50–55.
39.
SakamotoTAkiyamaSNarasakaT, et al.Anal intraepithelial neoplasia: precursor of anal squamous cell carcinoma. J Anus Rectum Colon2022; 6(2): 92–99.
40.
LeeGCKunitakeHMilchH, et al.What is the risk of anal carcinoma in patients with anal intraepithelial neoplasia III?Dis Colon Rectum2018; 61(12): 1350–1356.
41.
EjazMMubarakMAliTS, et al.Human papillomavirus-associated anal squamous intraepithelial lesions in men who have sex with men and transgender women living with and without HIV in Karachi Pakistan: implications for screening and prevention. BMC Infect Dis2021; 21(1): 1163.
42.
PalefskyJMHollyEARalstonML, et al.High incidence of anal high-grade squamous intra-epithelial lesions among HIV-positive and HIV-negative homosexual and bisexual men. AIDS1998; 12(5): 495–503.
43.
SalitIETinmouthJChongS, et al.Screening for HIV-associated anal cancer: correlation of HPV genotypes, p16, and E6 transcripts with anal pathology. Cancer Epidemiol Biomarkers Prev2009; 18(7): 1986–1992.
44.
de PokomandyARouleauDGhattasG, et al.HAART and progression to high-grade anal intraepithelial neoplasia in men who have sex with men and are infected with HIV. Clin Infect Dis2011; 52(9): 1174–1181.
45.
FriedmanHBSaahAJShermanME, et al.Human papillomavirus, anal squamous intraepithelial lesions, and human immunodeficiency virus in a cohort of gay men. J Infect Dis1998; 178(1): 45–52.
46.
van der ZeeRPRichelOvan NoeselCJM, et al.Cancer risk stratification of anal intraepithelial neoplasia in human immunodeficiency virus-positive men by validated methylation markers associated with progression to cancer. Clin Infect Dis2021; 72(12): 2154–2163.
47.
GuerendiainDGrigorescuRKirkA, et al.HPV status and HPV16 viral load in anal cancer and its association with clinical outcome. Cancer Med. 2022; 11(22): 4193–4203.
48.
PintoLAWilkinTJKempTJ, et al.Oral and systemic HPV antibody kinetics post-vaccination among HIV-positive and HIV-negative men. Vaccine2019; 37(18): 2502–2510.
49.
PalefskyJMGiulianoARGoldstoneS, et al.HPV vaccine against anal HPV infection and anal intraepithelial neoplasia. N Engl J Med2011; 365(17): 1576–1585.
50.
JouraEAGiulianoARIversenOE, et al.A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. N Engl J Med2015; 372(8): 711–723.
51.
PiyathilakeCJBadigaSKumarR, et al.A rigorous exploration of anal HPV genotypes using a Next-Generation Sequencing (NGS) approach in HIV-infected men who have sex with men at risk for developing anal cancer. Cancer Med2020; 9(2): 807–815.
52.
PalefskyJMLensingSYBelzerM, et al.High prevalence of anal high-grade squamous intraepithelial lesions, and prevention through human papillomavirus vaccination, in young men who have sex with men living with human immunodeficiency virus. Clin Infect Dis2021; 73(8): 1388–1396.
53.
DeshmukhAACantorSBFenwickE, et al.Adjuvant HPV vaccination for anal cancer prevention in HIV-positive men who have sex with men: the time is now. Vaccine2017; 35(38): 5102–5109.
54.
SoeNNOngJJMaX, et al.Should human papillomavirus vaccination target women over age 26, heterosexual men and men who have sex with men? A targeted literature review of cost-effectiveness. Hum Vaccines Immunother2018; 14(12): 3010–3018.
55.
ZhangJChenXYeY, et al.Increased CD4+ T cell count is associated with lower anal human papillomavirus prevalence among HIV-positive male cohort in Taizhou, China: a cross-sectional study. BMC Infect Dis2022; 22(1): 250.
56.
MavundzaEJWiyehABMahashaPW, et al.A systematic review of immunogenicity, clinical efficacy and safety of human papillomavirus vaccines in people living with the human immunodeficiency virus. Hum Vaccines Immunother2020; 16(2): 426–435.
57.
GosensKCMvan der ZeeRPvan HeukelomMLS, et al.HPV vaccination to prevent recurrence of anal intraepithelial neoplasia in HIV+ MSM. AIDS2021; 35(11): 1753–1764.
58.
WilkinTJChenHCespedesMS, et al.A randomized, placebo-controlled trial of the quadrivalent human papillomavirus vaccine in human immunodeficiency virus-infected adults aged 27 Years or older: AIDS clinical trials group protocol A5298. Clin Infect Dis2018; 67(9): 1339–1346.
59.
Hidalgo-TenorioCPasquauJOmar-MohamedM, et al.Effectiveness of the quadrivalent HPV vaccine in preventing anal ≥ HSILs in a Spanish population of HIV+ MSM aged > 26 years. Viruses2021; 13(2): 144.
60.
NyitrayAGDʼSouzaGStierEA, et al.The utility of digital anal rectal examinations in a public health screening program for anal cancer. J Low Genit Tract Dis2020; 24(2): 192–196.
61.
HillmanRJBerry-LawhornJMOngJJ, et al.International anal neoplasia society guidelines for the practice of digital anal rectal examination. J Low Genit Tract Dis2019; 23(2): 138–146.
62.
GaisaMMSigelKMDeshmukhAA, et al.Comparing anal cancer screening algorithms using cytology and human papillomavirus DNA testing in 3 high-risk populations. J Infect Dis2021; 224(5): 881–888.
63.
DarraghTMWinklerB. Screening for anal neoplasia: anal cytology - sampling, processing and reporting. Sex Health2012; 9(6): 556–561.
64.
ChiaoEYGiordanoTPPalefskyJM, et al.Screening HIV-infected individuals for anal cancer precursor lesions: a systematic review. Clin Infect Dis2006; 43(2): 223–233.
65.
KimuraCMSNahasCSRSilva-FilhoEV, et al.High-risk human papillomavirus test in anal smears: can it optimize the screening for anal cancer?AIDS2021; 35(5): 737–745.
66.
ParkIUPalefskyJM. Evaluation and management of anal intraepithelial neoplasia in HIV-negative and HIV-positive men who have sex with men. Curr Infect Dis Rep2010; 12(2): 126–133.
67.
PernotSBoucheronPPereH, et al.Comparison of anal cancer screening strategies including standard anoscopy, anal cytology, and HPV genotyping in HIV-positive men who have sex with men. Br J Cancer2018; 119(3): 381–386.
68.
ChanPSFangYChidgeyA, et al.Would Chinese men who have sex with men take up Human Papillomavirus (HPV) screening as an alternative prevention strategy to HPV vaccination?Front Med2022; 9: 904873.
69.
Heid-PicardBCochand-PriolletBRozenbergF, et al.Ambulatory anal self-sampling in MSM living with HIV, an acceptable and reliable screening method. PLoS One2021; 16(2): e0246338.
70.
EjazMEkströmAMAhmedA, et al.Human Papillomavirus associated prevention: knowledge, attitudes, and perceived risks among men who have sex with men and transgender women in Pakistan: a qualitative study. BMC Public Health2022; 22(1): 378.
71.
FenklEASchochetEJonesSG, et al.Evaluation of an HPV/anal cancer screening awareness program for HIV-infected men who have sex with men. J Assoc Nurses AIDS Care2015; 26(4): 492–497.
72.
LeeJYLensingSYBerry-LawhornJM, et al.Design of the ANal Cancer/HSIL Outcomes Research study (ANCHOR study): a randomized study to prevent anal cancer among persons living with HIV. Contemp Clin Trials2022; 113: 106679.
73.
KitamuraHAndoNMizushimaD, et al.Electrocautery ablation therapy for anal intraepithelial carcinoma with high-resolution anoscopy. J Infect Chemother2025; 31(3): 102608.
74.
VelaSVidelaSOrnelasA, et al.Effectiveness of physically ablative and pharmacological treatments for anal condyloma in HIV-infected men. PLoS One2018; 13(8): e0199033.
75.
MarksDKGoldstoneSE. Electrocautery ablation of high-grade anal squamous intraepithelial lesions in HIV-negative and HIV-positive men who have sex with men. J Acquir Immune Defic Syndr2012; 59(3): 259–265.
76.
DeshmukhAAChiaoEYCantorSB, et al.Management of precancerous anal intraepithelial lesions in human immunodeficiency virus-positive men who have sex with men: clinical effectiveness and cost-effectiveness. Cancer2017; 123(23): 4709–4719.
77.
PalefskyJMLeeJYJayN, et al.Treatment of anal high-grade squamous intraepithelial lesions to prevent anal cancer. N Engl J Med2022; 386(24): 2273–2282.
78.
NigroNDSeydelHGConsidineB, et al.Combined preoperative radiation and chemotherapy for squamous cell carcinoma of the anal canal. Cancer1983; 51(10): 1826–1829.
79.
RaoSAnandappaGCapdevilaJ, et al.A phase II study of retifanlimab (INCMGA00012) in patients with squamous carcinoma of the anal canal who have progressed following platinum-based chemotherapy (POD1UM-202). ESMO Open2022; 7(4): 100529.
80.
LonardiSPreteAAMoranoF, et al.Randomized phase II trial of avelumab alone or in combination with cetuximab for patients with previously treated, locally advanced, or metastatic squamous cell anal carcinoma: the CARACAS study. J Immunother Cancer2021; 9(11): e002996.
81.
CappelloCCumingTBowringJ, et al.High-resolution anoscopy surveillance after anal squamous cell carcinoma: high-grade squamous intraepithelial lesion detection and treatment may influence local recurrence. Dis Colon Rectum2020; 63(10): 1363–1371.
82.
BrogdenDRLKontovounisiosCChongI, et al.Local excision and treatment of early node-negative anal squamous cell carcinomas in a highly HIV prevalent population. Tech Coloproctol2021; 25(9): 1027–1036.
